SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

User Photo
VJOncology

2 years
1,080 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), a question arising is which drug is better. Speaking from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses this question.
Up Next Autoplay